Abstract

This study evaluated the outcomes of patients who underwent high-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (autoHSCT) for mantle cell non-Hodgkin's lymphoma and the effect of clinical and treatment characteristics. The clinical outcome and prognostic factors in 40 patients who underwent HDC and autoHSCT for mantle cell lymphoma between June 1991 and August 1998 were analyzed. With a median follow-up of 24 months for the surviving patients (range, 4-68 months), the 2-year overall survival was 65% and the 2-year event-free survival (EFS) was 36%. In univariate analysis, characteristics predictive of a poor EFS were blastic morphology (P = .019) and the patient having received 3 or more prior chemotherapy regimens (P = .004). In a multivariate analysis, the only factor associated with a poor EFS was the number of prior chemotherapy regimens. Those patients who received 3 or more prior therapies had a 2-year EFS of 0%, and those who received <3 therapies had a 2-year EFS of 45% (P = .004). Patients with mantle cell lymphoma can obtain prolonged EFS with HDC and autoHSCT; however, this strategy for prolonged EFS appears to work optimally in patients who are less heavily pretreated. Whether this therapy will increase the overall survival or EFS in patients receiving transplants in first complete remission will need to be tested in prospective randomized clinical trials.

Original languageEnglish (US)
Pages (from-to)640-645
Number of pages6
JournalBiology of Blood and Marrow Transplantation
Volume6
Issue number6
DOIs
StatePublished - Jan 1 2000

Fingerprint

Mantle-Cell Lymphoma
Hematopoietic Stem Cell Transplantation
Disease-Free Survival
Drug Therapy
Survival
Therapeutics
Non-Hodgkin's Lymphoma
Multivariate Analysis
Randomized Controlled Trials
Outcome Assessment (Health Care)
Transplants

Keywords

  • Autologous hematopoietic stem cell transplantation
  • High-dose chemotherapy
  • Mantle cell lymphoma
  • Non-Hodgkin's lymphoma

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Autologous Hematopoietic Stem Cell Transplantation for Mantle Cell Lymphoma. / Vose, Julie Marie; Bierman, Philip Jay; Weisenburger, Dennis D.; Lynch, James C.; Bociek, Robert G; Chan, Wing C.; Greiner, Timothy Charles; Armitage, James Olen.

In: Biology of Blood and Marrow Transplantation, Vol. 6, No. 6, 01.01.2000, p. 640-645.

Research output: Contribution to journalArticle

@article{a334115edf334679ab936b5da8b2313b,
title = "Autologous Hematopoietic Stem Cell Transplantation for Mantle Cell Lymphoma",
abstract = "This study evaluated the outcomes of patients who underwent high-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (autoHSCT) for mantle cell non-Hodgkin's lymphoma and the effect of clinical and treatment characteristics. The clinical outcome and prognostic factors in 40 patients who underwent HDC and autoHSCT for mantle cell lymphoma between June 1991 and August 1998 were analyzed. With a median follow-up of 24 months for the surviving patients (range, 4-68 months), the 2-year overall survival was 65{\%} and the 2-year event-free survival (EFS) was 36{\%}. In univariate analysis, characteristics predictive of a poor EFS were blastic morphology (P = .019) and the patient having received 3 or more prior chemotherapy regimens (P = .004). In a multivariate analysis, the only factor associated with a poor EFS was the number of prior chemotherapy regimens. Those patients who received 3 or more prior therapies had a 2-year EFS of 0{\%}, and those who received <3 therapies had a 2-year EFS of 45{\%} (P = .004). Patients with mantle cell lymphoma can obtain prolonged EFS with HDC and autoHSCT; however, this strategy for prolonged EFS appears to work optimally in patients who are less heavily pretreated. Whether this therapy will increase the overall survival or EFS in patients receiving transplants in first complete remission will need to be tested in prospective randomized clinical trials.",
keywords = "Autologous hematopoietic stem cell transplantation, High-dose chemotherapy, Mantle cell lymphoma, Non-Hodgkin's lymphoma",
author = "Vose, {Julie Marie} and Bierman, {Philip Jay} and Weisenburger, {Dennis D.} and Lynch, {James C.} and Bociek, {Robert G} and Chan, {Wing C.} and Greiner, {Timothy Charles} and Armitage, {James Olen}",
year = "2000",
month = "1",
day = "1",
doi = "10.1016/S1083-8791(00)70030-9",
language = "English (US)",
volume = "6",
pages = "640--645",
journal = "Biology of Blood and Marrow Transplantation",
issn = "1083-8791",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Autologous Hematopoietic Stem Cell Transplantation for Mantle Cell Lymphoma

AU - Vose, Julie Marie

AU - Bierman, Philip Jay

AU - Weisenburger, Dennis D.

AU - Lynch, James C.

AU - Bociek, Robert G

AU - Chan, Wing C.

AU - Greiner, Timothy Charles

AU - Armitage, James Olen

PY - 2000/1/1

Y1 - 2000/1/1

N2 - This study evaluated the outcomes of patients who underwent high-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (autoHSCT) for mantle cell non-Hodgkin's lymphoma and the effect of clinical and treatment characteristics. The clinical outcome and prognostic factors in 40 patients who underwent HDC and autoHSCT for mantle cell lymphoma between June 1991 and August 1998 were analyzed. With a median follow-up of 24 months for the surviving patients (range, 4-68 months), the 2-year overall survival was 65% and the 2-year event-free survival (EFS) was 36%. In univariate analysis, characteristics predictive of a poor EFS were blastic morphology (P = .019) and the patient having received 3 or more prior chemotherapy regimens (P = .004). In a multivariate analysis, the only factor associated with a poor EFS was the number of prior chemotherapy regimens. Those patients who received 3 or more prior therapies had a 2-year EFS of 0%, and those who received <3 therapies had a 2-year EFS of 45% (P = .004). Patients with mantle cell lymphoma can obtain prolonged EFS with HDC and autoHSCT; however, this strategy for prolonged EFS appears to work optimally in patients who are less heavily pretreated. Whether this therapy will increase the overall survival or EFS in patients receiving transplants in first complete remission will need to be tested in prospective randomized clinical trials.

AB - This study evaluated the outcomes of patients who underwent high-dose chemotherapy (HDC) and autologous hematopoietic stem cell transplantation (autoHSCT) for mantle cell non-Hodgkin's lymphoma and the effect of clinical and treatment characteristics. The clinical outcome and prognostic factors in 40 patients who underwent HDC and autoHSCT for mantle cell lymphoma between June 1991 and August 1998 were analyzed. With a median follow-up of 24 months for the surviving patients (range, 4-68 months), the 2-year overall survival was 65% and the 2-year event-free survival (EFS) was 36%. In univariate analysis, characteristics predictive of a poor EFS were blastic morphology (P = .019) and the patient having received 3 or more prior chemotherapy regimens (P = .004). In a multivariate analysis, the only factor associated with a poor EFS was the number of prior chemotherapy regimens. Those patients who received 3 or more prior therapies had a 2-year EFS of 0%, and those who received <3 therapies had a 2-year EFS of 45% (P = .004). Patients with mantle cell lymphoma can obtain prolonged EFS with HDC and autoHSCT; however, this strategy for prolonged EFS appears to work optimally in patients who are less heavily pretreated. Whether this therapy will increase the overall survival or EFS in patients receiving transplants in first complete remission will need to be tested in prospective randomized clinical trials.

KW - Autologous hematopoietic stem cell transplantation

KW - High-dose chemotherapy

KW - Mantle cell lymphoma

KW - Non-Hodgkin's lymphoma

UR - http://www.scopus.com/inward/record.url?scp=0033660394&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033660394&partnerID=8YFLogxK

U2 - 10.1016/S1083-8791(00)70030-9

DO - 10.1016/S1083-8791(00)70030-9

M3 - Article

C2 - 11128815

AN - SCOPUS:0033660394

VL - 6

SP - 640

EP - 645

JO - Biology of Blood and Marrow Transplantation

JF - Biology of Blood and Marrow Transplantation

SN - 1083-8791

IS - 6

ER -